The Senate Appropriations Committee met July 31 to markup legislation that would fund the Department of Health and Human Services – including an additional $400 million for the National Institutes of Health. The increase in NIH funding repudiates the Trump administration’s efforts to drastically cut those appropriations, which is an outcome marking a clear win for companies in the life sciences. Read More
Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection of cardiovascular disease, Ross Upton, CEO and founder of Ultromics told BioWorld. Read More
Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression of MSA. Developed using deep learning methods, the MSA-AI offers a superior, objective and quantifiable measure of brain atrophy in MSA patients. Read More
Med-tech firms raising money in public or private financings, including: Inspiremd, Magnetiq Eye, Myriad Genetics, Shoulder Innovations, Ultromics. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bioaffinity Technologies, Etiometry, Evvy, Guardant Health, Omron Healthcare, Preludedx. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptitude Medical, Arkstone Medical, Paragon Genomics, Genecast, Natera, Newgenivf, Pavmed, Royal Philips, Vivex, Viz.ai. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alafair Biosciences, Evoendo, Setpoint Medical. Read More
